Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 12/20 | 1.00 |
| ▸ | DRD1 | P21728 | 9/20 | 1.00 |
| ▸ | DRD2 | P14416 | 8/20 | 1.00 |
| ▸ | HTR7 | P34969 | 8/20 | 1.00 |
| ▸ | HTR2C | P28335 | 8/20 | 1.00 |
| ▸ | PNPLA2 | Q96AD5 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 8/20 | 0.80 |
| ▸ | HTR2B | P41595 | 8/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.80 |
| ▸ | TDP2 | O95551 | 2/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.80 |
| ▸ | MAPT | P10636 | 2/20 | 0.80 |
| ▸ | CASP3 | P42574 | 2/20 | 0.80 |
| ▸ | RAD52 | P43351 | 2/20 | 0.80 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.80 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.80 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.80 |
| ▸ | PTPRCAP | Q14761 | 1/20 | 0.80 |
| ▸ | APAF1 | O14727 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nuciferine SCHEMBL29521272 | 1.00 | HTR2A (1.00) | HTR2ADRD1DRD2HTR7HTR2C | |
| (+/-)-Nuciferine SCHEMBL634777 | 1.00 | HTR2A (1.00) | HTR2ADRD1DRD2HTR7HTR2C | |
| (+/-)-Nuciferine SCHEMBL11710956 | 0.99 | HTR2A (0.98) | HTR2ADRD1DRD2HTR7HTR2C | |
| Glaucine SCHEMBL30213021 | 0.89 | HTR2A (1.00) | HTR2ADRD1DRD2HTR7HTR2C | |
| Glaucine SCHEMBL146441 | 0.89 | HTR2A (1.00) | HTR2ADRD1DRD2HTR7HTR2C | |
| Glaucine SCHEMBL29735463 | 0.89 | HTR2A (1.00) | HTR2ADRD1DRD2HTR7HTR2C | |
| Glaucine SCHEMBL3040938 | 0.89 | HTR2A (1.00) | HTR2ADRD1DRD2HTR7HTR2C | |
| SCHEMBL11710907 | 0.88 | HTR2A (0.79) | HTR2ADRD1DRD2HTR7HTR2C | |
| Glaucine SCHEMBL11249152 | 0.88 | KDM4E (1.00) | HTR2ADRD1DRD2HTR7HTR2C | |
| Glaucine SCHEMBL11166124 | 0.88 | HTR2A (0.97) | HTR2ADRD1DRD2HTR7HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110376303-B | Extraction process for optimizing throat-clearing and throat-moistening preparation through orthogonal test | 西南医科大学 | 2022-04-19 | — | — | CN | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4471790-B1 | SYSTEM AND METHOD FOR DETERMINING MICROBIOME FROM HOST METABOLOME USING A MACHINE LEARNING MODEL | MICROBIOTX HEALTH PRIVATE LTD (IN) | 2026-04-01 | — | — | EP | disclosed |
| EP-4495102-A4 | SYNTHESIS METHOD FOR NUCIFERINE OR DERIVATIVE THEREOF, NUCIFERINE DERIVATIVE AND APPLICATION THEREOF | HUAQIAO UNIVESITY (CN) | 2025-07-16 | — | — | EP | disclosed |
| US-20250197356-A1 | METHOD FOR SYNTHESIZING NUCIFERINE OR DERIVATIVE THEREOF, DERIVATIVE OF NUCIFERINE AND USE THEREOF | HUAQIAO UNIVERSITY (CN) | 2025-06-19 | — | — | US | disclosed |
| CN-120053346-A | Lotus seedpod or lotus seed shell extract and preparation method and application thereof | 湖南科技大学 | 2025-05-30 | — | — | CN | disclosed |
| EP-4495102-A1 | SYNTHESIS METHOD FOR NUCIFERINE OR DERIVATIVE THEREOF, NUCIFERINE DERIVATIVE AND APPLICATION THEREOF | Huaqiao Univesity (CN) | 2025-01-22 | — | — | EP | disclosed |
| US-20240404637-A1 | SYSTEM AND METHOD FOR DETERMINING MICROBIOME FROM HOST METABOLOME USING A MACHINE LEARNING MODEL | MICROBIOTX HEALTH PRIVATE LIMITED (IN) | 2024-12-05 | — | — | US | disclosed |
| EP-4471790-A1 | SYSTEM AND METHOD FOR DETERMINING MICROBIOME FROM HOST METABOLOME USING A MACHINE LEARNING MODEL | MicrobioTx Health Private Limited (IN) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023178809-A1 | SYNTHESIS METHOD FOR NUCIFERINE OR DERIVATIVE THEREOF, NUCIFERINE DERIVATIVE AND APPLICATION THEREOF | 华侨大学 | 2023-09-28 | — | — | WO | disclosed |
| CN-104873529-A | Antiviral drug composition containing nuciferine | UNIVTAISHAN MEDICAL | 2015-09-02 | — | — | CN | disclosed |
| CN-104523730-A | Pharmaceutical composition for treating phthisis | JINAN XINGYI MED TECH CO LTD | 2015-04-22 | — | — | CN | disclosed |
| CN-104523731-A | Pharmaceutical composition for treating pulmonary tuberculosis | JINAN XINGYI MED TECH CO LTD | 2015-04-22 | — | — | CN | disclosed |
| CN-104523732-A | Pharmaceutical composition for treating phthisis | JINAN XINGYI MED TECH CO LTD | 2015-04-22 | — | — | CN | disclosed |
| CN-104523729-A | Pharmaceutical composition for treating phthisis | JINAN XINGYI MED TECH CO LTD | 2015-04-22 | — | — | CN | disclosed |
| CN-104510733-A | Use of alkaloid as inflammatory cancer translation blocking and tumor preventing medicine | UNIV TSINGHUA | 2015-04-15 | — | — | CN | disclosed |
| CN-104473903-A | Nuciferine oral nano-administration system and preparation method thereof | SHANGHAI 1ST PEOPLES HOSPITAL | 2015-04-01 | — | — | CN | disclosed |
| CN-104473943-A | Pharmaceutical composition used for treating diabetes | JINAN XINGYI MED TECH CO LTD | 2015-04-01 | — | — | CN | disclosed |
| CN-102949299-B | Application of nuciferine or plant extract containing nuciferine | SHANGHAI LAIBO BIO CHEMICAL CO LTD | 2014-08-06 | — | — | CN | disclosed |
| CN-102949299-A | Application of nuciferine or plant extract containing nuciferine | SHANGHAI LAIBO BIO CHEMICAL CO LTD | 2013-03-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197356-A1 | METHOD FOR SYNTHESIZING NUCIFERINE OR DERIVATIVE THEREOF, DERIVATIVE OF NUCIFERINE AND USE THEREOF | NUCB2, NISCH, CYP46A1 | HTR2A 1455/4885DRD1 1315/4885DRD2 1061/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | HTR2A 1608/4885DRD1 4602/4885DRD2 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.